Prosecution Insights
Last updated: May 29, 2026

Innate Pharma

5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days

Portfolio Summary

5
Total Pending OAs
3
Non-Final OAs
1
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

3
Overdue
0
Due this week
1
Due this month
1
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (3)Due ≤ 30 days (1)Due ≤ 60 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (20%)
1
Easy (20%)
3
Unknown (60%)

Rejection Statute Mix

BucketCases
§103 only1 (20%)
§112 only1 (20%)
No statute on record3 (60%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

5
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

50 h
Manual time on pending OAs
10 h
Time saved (low, 20%)
18 h
Time saved (mid, 35%)
0.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
ROONEY, NORA MAUREEN 1 60.5% +23.2%
HUYNH, PHUONG N 1 65.7% +53.3%
JOHNSON, TIRONE DEREK 1
PUTTLITZ, KARL J 1 69.1% +18.4%
MOSELEY II, NELSON B 1 68.1% +41.7%

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
18432126 VARIABLE REGIONS FOR NKP46 BINDING PROTEINS ROONEY, NORA MAUREEN 72d overdue
18490804 MULTISPECIFIC NKp46 BINDING PROTEINS HUYNH, PHUONG N 44d overdue
18331966 NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES PUTTLITZ, KARL J 15d overdue
18020436 CELL SURFACE MICA AND MICB DETECTION USING ANTIBODIES MOSELEY II, NELSON B 28d

Top Art Units

Art UnitApps
1641 2
1675 1
1646 1
1642 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18432126 VARIABLE REGIONS FOR NKP46 BINDING PROTEINS ROONEY, NORA MAUREEN 1641 Other Final Rejection 72d overdue Pending Feb 05, 2024
18490804 MULTISPECIFIC NKp46 BINDING PROTEINS HUYNH, PHUONG N 1641 §112 Non-Final OA 44d overdue Pending Oct 20, 2023
18283385 MULTISPECIFIC PROTEINS COMPRISING AN NKP46-BINDING SITE, A CANCER ANTGIENGE BINDING SITE FUSED TO A CYTOKINE FOR NK CELL ENGAGING JOHNSON, TIRONE DEREK 1675 §103 Non-Final OA 34d Pending Sep 21, 2023
18331966 NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES PUTTLITZ, KARL J 1646 Other Non-Final OA 15d overdue Pending Jun 09, 2023
18020436 CELL SURFACE MICA AND MICB DETECTION USING ANTIBODIES MOSELEY II, NELSON B 1642 Other Non-Final OA 28d Pending Feb 09, 2023

Managing Innate Pharma's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month